Planned maintenance may cause outages to the Department of Health and Aged Care’s network from 5:15 pm AEDT on 30 November to 10:00 pm AEDT on 1 December 2024. Access to TGA databases such as TBS Portal, ARTG and DAEN may be affected. We apologise for any inconvenience.
(Approval lapsed) Dicloxacillin Sodium Capsules USP 250mg
Section 19A approved medicine
(Approval lapsed) Dicloxacillin Sodium Capsules USP 250mg
Section 19A approval holder
Medsurge Healthcare Pty Ltd ABN 92 124 728 892
Phone
1300 788 261
Approved until
Status
Expired
Medicines in short supply/unavailable
DISTAPH 250 dicloxacillin 250mg (as sodium) capsule bottle - ARTG 226506
DICLOXACILLIN MYLAN 250 dicloxacillin (as sodium) 250 mg capsule bottle - ARTG 289105
DICLOXACILLIN MYLAN 250 dicloxacillin (as sodium) 250 mg capsule bottle - ARTG 289105
Indication(s)
Treatment of confirmed or suspected staphylococcal and other Gram positive coccal infections, including skin and skin structure and wound infections, infected burns, cellulitis, osteomyelitis and pneumonia (note: benzylpenicillin is the drug of choice for the treatment of streptococcal pneumonia).
Bacteriological studies should be performed to determine the causative organisms and their susceptibility to dicloxacillin. Dicloxacillin has less intrinsic antibacterial activity and a narrower spectrum than benzylpenicillin.
Dicloxacillin should therefore not be used in infections due to organisms susceptible to benzylpenicillin.
Important Note: When it is judged necessary that treatment is initiated before definitive culture and sensitivity results are known, if the microbiology report later indicates that the infection is due to an organism other than a benzylpenicillin resistant staphylococcus sensitive to dicloxacillin, the physician is advised to continue therapy with a drug other than dicloxacillin or any other penicillinase-resistant penicillin.